Your browser doesn't support javascript.
loading
Acceptability of on-site rapid HIV/HBV/HCV testing and HBV vaccination among three at-risk populations in distinct community-healthcare outreach centres: the ANRS-SHS 154 CUBE study.
Calin, Ruxandra; Massari, Véronique; Pialoux, Gilles; Reydellet, Nelly; Plenel, Eve; Chauvin, Carole; Jauffret-Roustide, Marie; Day, Nesrine; Kreplak, Georges; Maresca, Anaenza Freire; Derche, Nicolas; Louis, Sandra; Pol, Stanislas; Doré, Véronique; Rouzioux, Christine; Chauvin, Pierre.
Afiliação
  • Calin R; Service de Maladies Infectieuses, Hôpital Tenon, Groupe Hospitalier Est, AP-HP, 4 rue de la Chine, 75970, Paris, Cedex 20, France. ruxandra.calin@aphp.fr.
  • Massari V; Inserm, IPLESP, ERES, Institut Pierre-Louis d'épidémiologie et de santé publique, Sorbonne Université, 75012, Paris, France. ruxandra.calin@aphp.fr.
  • Pialoux G; Inserm, IPLESP, ERES, Institut Pierre-Louis d'épidémiologie et de santé publique, Sorbonne Université, 75012, Paris, France.
  • Reydellet N; Service de Maladies Infectieuses, Hôpital Tenon, Groupe Hospitalier Est, AP-HP, 4 rue de la Chine, 75970, Paris, Cedex 20, France.
  • Plenel E; Sorbonne Université, UPMC Université, Paris 06, France.
  • Chauvin C; Le Kiosque, Checkpoint-Paris, Groupe SOS, Paris, France.
  • Jauffret-Roustide M; Le Kiosque, Checkpoint-Paris, Groupe SOS, Paris, France.
  • Day N; Le Kiosque, Checkpoint-Paris, Groupe SOS, Paris, France.
  • Kreplak G; Cermes3, Inserm U988, CNRS UMR8211, EHESS, Université de Paris, Paris, France.
  • Maresca AF; Cermes3, Inserm U988, CNRS UMR8211, EHESS, Université de Paris, Paris, France.
  • Derche N; Laboratoires Centre Biologique Chemin Vert (CBCV), Paris, France.
  • Louis S; Laboratoires Centre Biologique Chemin Vert (CBCV), Paris, France.
  • Pol S; ARCAT, Pasaje Latino, Groupe SOS, Paris, France.
  • Doré V; AP-HP, Hôpital Ambroise Pare, Service de Médecine Interne, Boulogne-Billancourt, France.
  • Rouzioux C; Le Kiosque, Checkpoint-Paris, Groupe SOS, Paris, France.
  • Chauvin P; CSAPA 110 Les Halles, ARCAT, Groupe SOS, Paris, France.
BMC Infect Dis ; 20(1): 851, 2020 Nov 16.
Article em En | MEDLINE | ID: mdl-33198672
ABSTRACT

BACKGROUND:

HIV, HBV and HCV infections continue to represent major health concerns, especially among key at-risk populations such as men who have sex with men (MSM), people who inject drugs (PWIDs), transgender women (TGW) and sex workers (SW). The objective of the ANRS-CUBE study was to evaluate the acceptability of a healthcare, community-based strategy offering a triple rapid HIV-HBV-HCV testing, and HBV vaccination, targeted at three priority groups (MSM, PWIDs and TGW/SWs), in three community centers, in the Paris area.

METHODS:

This longitudinal multicentric non-randomized study included all adult volunteers attending one of the three specialized community centers in Paris, between July 2014 and December 2015. HIV, HBV and HCV status and acceptability of HBV vaccination were evaluated.

RESULTS:

A total of 3662, MSM, 80 PWIDs and 72 TGW/SW were recruited in the three centers respectively. Acceptability of rapid tests was 98.5% in MSM and 14.9% in TGW/SWs, but could not be estimated in PWIDs since the number of users attending and the number of proposals were not recorded. User acceptability of HBV vaccination was weak, only 17.9% of the eligible MSM (neither vaccinated, nor infected) agreed to receive the first dose, 12.2% two doses, 5.9% had a complete vaccination. User acceptability of HBV vaccination was greater in PWIDs and TGW/SWs, but decreased for the last doses (66.7 and 53.3% respectively received a first dose, 24.4 and 26.7% a second dose and 6.7 and 0% a third dose). Fifty-three participants (49 MSM and 4 PWIDs) were discovered HIV positive, more than half with a recent infection. All but two HIV positive participants were linked to appropriate care in less than one month.

CONCLUSIONS:

Rapid HIV-HCV-HBV screening showed a very high level of acceptability among MSM. Efforts need to be made to improve immediate acceptability for HBV vaccination, especially among MSM, and follow-up doses compliance. Our results show the important role of community centers in reaching targets, often fragile, populations, while also suggesting the need to reinforce on-site human support in terms of testing and vaccination, especially when addressing PWIDs.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Virais / Infecções por HIV / Vírus da Hepatite B / HIV-1 / HIV-2 / Vacinação / Hepacivirus / Hepatite B Crônica / Hepatite C Crônica Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adolescent / Adult / Female / Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Virais / Infecções por HIV / Vírus da Hepatite B / HIV-1 / HIV-2 / Vacinação / Hepacivirus / Hepatite B Crônica / Hepatite C Crônica Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adolescent / Adult / Female / Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article